When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
WIZP - Wize Pharma completes enrollment in post-marketing study of EyeCon eye drop
Wize Pharma Inc
Wize Pharma (OTCQB:WIZP) has completed enrollment in a Phase 4 clinical trial evaluating eye drop LO2A, branded as EyeCon in Israel, for the symptomatic treatment of dry eye syndrome (DES) in patients with an autoimmune disorder called Sjögren's syndrome (the immune system attacks glands that make tears and saliva causing dry eyes and mouth).
More news on: Wize Pharma, Inc., Healthcare stocks news,